The typical IGF-1 DES researcher is an advanced bodybuilder or physique-focused lifter who has a specific underdeveloped muscle group they cannot bring up with training alone. They have already exhausted volume manipulation, technique changes, and frequency adjustments. They are willing to inject a small molecule directly into a target muscle before training that muscle, and they understand that the entire reason this works is the short half-life.
IGF-1 DES (1-3) is a truncated insulin-like growth factor 1 with the first three amino acids of the N-terminus removed. That small structural change weakens its binding to IGFBPs (and binding proteins normally extend half-life by carrying the molecule in circulation), so most of the molecule clears within 20 to 30 minutes of injection. That rapid clearance is the entire point. It is what keeps the active signal local to the injection site instead of spreading across the body the way IGF-1 LR3 does.
What IGF-1 DES actually is
Sequence: human IGF-1 minus the first three N-terminal amino acids (the GPE tripeptide). Molecular weight roughly 7400 Daltons. It was characterized in the late 1980s and early 1990s as a research tool for studying IGF-1 receptor biology in cell culture, where its IGFBP-evading profile and clean receptor binding made it useful. It later moved into performance research as the short-acting counterpart to IGF-1 LR3.
The mechanism in plain English
IGF-1 DES binds the IGF-1 receptor on the muscle tissue it is injected into. Activation of the receptor triggers satellite cell proliferation (the cells responsible for adding new muscle nuclei) and acutely raises local protein synthesis. Because the molecule clears in 20 to 30 minutes, the signal stays largely confined to the injection site. Repeated injections in the same site across multiple training sessions create a local hypertrophy signal that adds to whatever signal the training itself produces.
Why timing to the training session matters
Mechanical stimulus from training, especially in the eccentric (lengthening) phase of contraction, primes satellite cells for activation. IGF-1 DES injected 15 to 30 minutes before training the target muscle ensures the receptor activation peaks during the window when satellite cells are most responsive. Injecting hours before or after training wastes most of the half-life on a muscle that is not in its sensitized state. The timing is not optional for the protocol to work as designed.
Quick reference table
| Spec | Value | Note |
|---|---|---|
| Sequence | IGF-1 minus first three N-terminal amino acids | ~7400 Da |
| Half-life | ~20 to 30 minutes | Why it is site-targeted |
| Standard dose | 30 to 75 mcg into target muscle | Per training session for that muscle |
| Timing | 15 to 30 min pre-workout | Matches peak satellite cell response |
| Cycle window | 4 to 6 weeks per muscle group | Then rotate to a different group |
| Hypoglycemia risk | Lower than LR3, still real | Pre-workout carbs recommended |
What IGF-1 DES researchers track
Target muscle circumference (cold, in the morning, measured weekly) is the primary signal. Strength on the lifts that target the muscle group is the secondary signal. Side-to-side symmetry photos every 2 weeks are useful for the typical use case of bringing up a lagging single side. Glucose during and immediately after the training session is worth a CGM check during the first 2 weeks of any new protocol. Subjective pump quality during training of the dosed muscle group is a real-time confirmation the molecule is active locally.
Why DES is not for general mass
Researchers wanting body-wide growth signal will get poor return injecting DES into one muscle three times per week. The molecule clears before it can affect anything other than the local tissue. For general mass phase work, IGF-1 LR3 is the systemic anabolic signal that actually moves whole-body composition. DES is specifically for the case where one muscle group is the bottleneck and direct local stimulation is the only lever left.
Compared to IGF-1 LR3
LR3 lasts 20 to 30 hours and acts body-wide. DES lasts 20 to 30 minutes and stays local. LR3 is the chronic mass phase signal. DES is the surgical strike on a single muscle group. LR3 hypoglycemia risk is high because the molecule is active across the full day. DES hypoglycemia risk is real but contained to a short window post-injection. The two molecules answer different questions and the choice between them is determined by what the researcher is actually trying to accomplish.
External authority and source reading
The IGF-1 DES truncated form and its IGFBP-binding profile were characterized by Sara and Hall (Physiological Reviews) and Ballard et al. (Biochemical Journal) in the late 1980s and early 1990s. The satellite cell biology that explains why pre-training local injection works has been documented in Adams and McCue (Journal of Applied Physiology) and subsequent muscle hypertrophy literature in Medicine and Science in Sports and Exercise.
Compliance frame
IGF-1 DES is not FDA-approved. It is sold in the US as research-use-only material for in-vitro and laboratory study. Aion ships IGF-1 DES with research-grade labeling and a third-party COA. Any decision about your own use is a conversation for a qualified clinician familiar with peptide research.
Bottom line
IGF-1 DES is the precision tool for one specific problem: a single muscle group that will not respond to training the way the rest of the body does. Its short half-life is the feature that lets it stay local. Time it to the training session, run a 4 to 6 week block per muscle group, and rotate. For anything broader than that, LR3 or a GH-axis stack is the right answer.